---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018837"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:46:32.312915+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC

## Summary
- Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.
- Gross margin improved to ~50% in Q4; cash $303M funds operations into Q3 2027.
- FDA Fast Track granted for lifileucel in second-line advanced nonsquamous NSCLC; potential launch 2H27.
- Real-world Amtagvi ORR ~44% at Tandem Meetings; 52% in patients with ≤2 prior lines.
- Sarcoma early data: 50% ORR (6 evaluable); registrational trial to start Q2 2026.

## SEC filing metadata
- accession: 0001104659-26-018837
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/0001104659-26-018837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/tm266992d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018837
- JSON: https://secwatch.observer/filing/0001104659-26-018837.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.